Towards this direction, EPHB4/ephrin-B2 signaling is explored as an antiangiogenic target, with anti-EPHB4 monoclonal antibodies successfully blocking EPHB4 signaling [89,90,91], while inhibition of EPHA2 and EPHB1-3 forward signaling in gliomas is associated with a dose-dependent reduction in cell invasion [92]. The gene discussed is EPHB1; the disease is central nervous system cancer.